Management of Profuse Sweating During Irinotecan Infusion
This is acute cholinergic syndrome from irinotecan, and you should immediately administer atropine 0.25 to 1 mg intravenously or subcutaneously to abort the reaction. 1
Understanding the Clinical Picture
Profuse sweating at rest without diarrhea or fever during or shortly after irinotecan infusion represents early cholinergic syndrome, a well-recognized acute toxicity of irinotecan. This occurs due to excessive acetylcholine activity and is distinct from the late-onset diarrhea that develops >24 hours post-infusion 1.
Key Clinical Features to Recognize
The sweating (diaphoresis) you're observing is part of a constellation of cholinergic symptoms that may include:
- Diaphoresis (what your patient has)
- Abdominal cramping/bloating
- Early-onset diarrhea (during or within hours of infusion)
- Rhinorrhea and lacrimation
- Facial flushing
- Bradycardia (requires careful monitoring)
- Salivation
Immediate Management Algorithm
Step 1: Administer Atropine
- Dose: 0.25 to 1 mg IV or subcutaneous
- Timing: Give immediately when cholinergic symptoms appear
- Contraindication check: Ensure no clinical contraindications to atropine exist
- This is the FDA-recommended intervention and should be considered both therapeutically (when symptoms occur) and prophylactically for subsequent cycles 1
Step 2: Monitor Vital Signs
- Check heart rate specifically for bradycardia
- Monitor blood pressure
- Assess for progression of symptoms
Step 3: Consider Infusion Rate Modification
- Slowing the irinotecan infusion rate may help manage symptoms 3
- The standard 90-minute infusion can be extended if needed
Step 4: Reassure Patient and Staff
- These symptoms are self-limited and resolve within hours of completing the infusion 3
- No long-term sequelae occur from cholinergic syndrome
- This is not an allergic reaction requiring discontinuation of therapy
Risk Factors to Note
Combination chemotherapy significantly increases cholinergic syndrome risk. Patients receiving irinotecan plus 1-2 additional cytotoxic agents have 4-4.5 times higher odds of developing cholinergic syndrome compared to irinotecan monotherapy 2. This does not apply to molecularly targeted agents added to the regimen.
Management for Future Cycles
Prophylactic Atropine
- Strongly consider prophylactic atropine before subsequent irinotecan infusions in this patient
- Same dosing: 0.25 to 1 mg IV/SC prior to irinotecan administration
- This can prevent recurrence of cholinergic symptoms 1
Dose Modification Considerations
- Cholinergic syndrome alone does not require irinotecan dose reduction
- Dose reductions are reserved for severe diarrhea (late-onset) or severe myelosuppression 1
- Dose alterations have not been shown to impact dysarthria or other cholinergic manifestations 3
Critical Pitfall to Avoid
Do not confuse early cholinergic syndrome with late-onset diarrhea. They are distinct entities:
- Early (cholinergic): During or within 24 hours of infusion, accompanied by other cholinergic symptoms, managed with atropine
- Late: >24 hours post-infusion, can be life-threatening, requires loperamide, fluid/electrolyte replacement, and potential dose reduction 1
Your patient's profuse sweating without diarrhea or fever is the early form and requires atropine, not loperamide or antibiotics.
Documentation and Education
- Document the cholinergic reaction in the patient's chart
- Educate infusion nurses to recognize these symptoms early
- Counsel the patient that this is expected, manageable, and not a reason to discontinue potentially beneficial cancer therapy 3
- Plan prophylactic atropine for subsequent cycles